4 Healthcare Stock Stories for Weekend Wellness
Bristol-Myers Squibb Company (NYSE:BMY) Closing price $36.97
On Friday, The Medicines Company said that the global license and two-year collaboration with Bristol-Myers Squibb for Recothrom, a recombinant thrombin okayed by the FDA accord which was first announced in December. The parties have satisfied all required regulatory and closing conditions.
Biogen IDEC (NASDAQ:BIIB): Closing price $164.44
Biogen and the Swedish Orphan Biovitrum have released data that confirmed the ability of investigational recombinant factors VIII Fc fusion protein (rFVIIIFc) and IX Fc fusion protein (rFIXFc) to give long-lasting protection from bleeding with fewer injections than are needed with the current standard of care for persons suffering from hemophilia. The data come from the largest phase 3 registrational studies conducted in hemophilia thus far, and were presented this week at the 6th Annual Congress of the European Association for Haemophilia and Allied Disorders.
Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.
Medgenics (NYSE:MDGN): Closing price $5.17
Medgenics reported Friday that it has priced an underwritten public offering of 5.6 million shares of common stock and Series 2013-A warrants to buy up to a total of 2.8 million shares of common stock at an initial exercise price of $6.78. The shares and the warrants will be sold together as a fixed combination, with each comprised of one share of common stock and a warrant to purchase one-half of a share of common stock at a price to the public of $5.25 per fixed combination, with the shares of common stock and warrants to be issued separately. Gross proceeds to Medgenics will be $29.4 million. The offering should close on February 13th, subject to customary closing conditions. The firm is the developer of a novel platform tech for the sustained production and delivery of therapeutic proteins in patients using their own tissue.
Oncolytics Biotech (NASDAQ:ONCY): Closing price $4.35
The firm announced on Friday results examining percent overall tumour shrinkage data from its United States Phase 2 clinical trial in patients with squamous cell carcinoma of the lung using intravenous administration of Reolysinin combination with carboplatin and paclitaxel (REO 021). The analysis examined percent best overall tumour changes between pre-treatment and as many as six treatment cycles. Of 20 evaluable patients, 95 percent exhibited overall tumour shrinkage.